Treatment of Port‐Wine Birthmarks Using a Large‐Spot, Variable Sequenced, Long‐Pulsed KTP‐Laser—A Retrospective Analysis

TL;DR

A new laser treatment for port-wine birthmarks shows significant improvement in color and size with no serious side effects.

Contribution

Demonstrates the safety and efficacy of a new KTP laser for port-wine birthmarks over a 3-year period.

Findings

PWBs lightened by an average of 75.7% using the KTP laser.

Lesion surface area decreased by 25.3% with no severe adverse events.

The KTP laser could serve as a safe alternative to pulsed-dye lasers.

Abstract

Pulsed‐dye lasers (PDLs) are currently regarded as the gold standard for treating port‐wine birthmarks (PWBs). Recently, the large‐spot, variable‐sequenced, long‐pulsed potassium titanyl phosphate laser (KTP) has been introduced as a promising alternative for addressing dermatologic vascular lesions. Despite its growing use, data on the efficacy and safety of this technology in treating PWBs over an extended period remain limited.

To evaluate the efficacy and safety of a large‐spot, variable‐sequenced, long‐pulsed KTP in the treatment of PWBs over 3 years.

A retrospective analysis was conducted on PWB patients treated with the KTP between October 2021 and October 2024. Treatment outcomes were assessed using colorimetric analysis based on the CIE L*a*b* color space system and by measuring the surface area of the lesions. All adverse events (AEs) were documented.

A total of 69 patients were included, with a mean age of 36.5 ± 15.6 years. 59.4% were female. Colorimetric analysis revealed an average lightening of PWBs by 75.7% ± 36.1%. Additionally, the surface area of the lesions decreased by 25.3% ± 24.4%. No severe AEs, such as post‐inflammatory hyperpigmentation or scarring, were observed.

This study highlights the potential of large‐spot, variable‐pulsed KTP as a safe and effective alternative for treating PWBs, demonstrating significant lesion lightening and surface area reduction. With no severe AEs observed, the findings suggest that this technology could complement or serve as an alternative to PDLs. Further prospective studies are warranted to optimize treatment protocols and evaluate long‐term outcomes compared to PDL and other vascular treatment options.

Figures